 | | Vol. 23.34 – 3 October, 2022 |
| |
|
|
| Using multiple in vivo tumor models and clinical data, researchers reported that CAR activation in natural killer (NK) cells promoted transfer of the CAR cognate antigen from tumor to NK cells.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors gene-engineered A. fumigatus–specific chimeric antigen receptor CAR T cells and demonstrated their ability to confer antifungal reactivity in preclinical models in vitro and in vivo.
[Science Translational Medicine] |
|
|
|
| A vitality-enhanced dual-modal tracking system was designed to improve engraftment efficiency and was utilized to noninvasively explore the fate of intravenous transplanted human umbilical cord-derived MSCs during long-term treatment of ischemic stroke.
[Small] |
|
|
|
| A total of 97% of subjects underwent successful study product injections; all allo-mesenchymal stromal cells–assigned subjects received the target dose of cells.
[JACC-CardioOncology] |
|
|
|
| The in vivo antitumour activity of mesothelin CAR T cells was verified using a patient-derived xenograft mouse model with human tumour-derived cells.
[Cancer Immunology, Immunotherapy] |
|
|
|
| By using ISL1-overexpressing bone marrow mesenchymal stem cells (BMSCs) and the subtherapeutic doses of islets for co-transplantation, scientists managed to reduce the apoptosis and improve the survival rate of the grafts.
[Cellular and Molecular Life Sciences] |
|
|
|
| The authors constructed a cellular remodeling landscape and to identify the key cell subpopulations and important genes driving bladder remodeling.
[Cell Proliferation] |
|
|
|
| Investigators evaluated the characteristics, outcomes, and prognostic factors of allogeneic hematopoietic cell transplantation in recipients with juvenile myelomonocytic leukemia.
[Bone Marrow Transplantation] |
|
|
|
| Researchers successfully constructed CD19-specific armored CAR-T cells overexpressing IL-I5 and IL-15 receptor alpha.
[Journal of Translational Medicine] |
|
|
|
|
| Althought emerging smart cell engineering capabilities have yet to be fully implemented in the clinic, investigators argue here that they will become much more powerful when combined with machine learning analysis of genomic data.
[Nature Reviews Cancer] |
|
|
|
| Scientists discuss the current evidence and future directions of cellular therapies for the treatment of systemic lupus erythematous, including hematopoietic stem cell transplantation and advanced regulatory T cell–based cellular therapies.
[Journal of Allergy and Clinical Immunology] |
|
|
|
| The authors review animal models of regenerative biology and organ models involved in regenerative medicine, with a focus on limb/fin/digit-tip regeneration.
[Water Biology and Security] |
|
|
|
|
| Immunis, Inc. has formally signed a clinical trial agreement with California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase I/IIa clinical trials.
[Immunis, Inc. (Business Wire)] |
|
|
|
|
| December 8 – 10, 2022
Los Angeles, California, United States |
|
|
|
|
|
| | Alia Therapeutics – Trento, Italy |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Yale University – New Haven, Connecticut, United States |
|
|
|
| | UC San Francisco – San Francisco, California, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
